Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

This study has been completed.
Information provided by:
St Stephens Aids Trust Identifier:
First received: February 22, 2010
Last updated: August 13, 2010
Last verified: August 2010

The purpose of the study is to look at the levels of three HIV medications darunavir, ritonavir and atazanavir in the blood after the drug intake has been stopped in order to understand how long these drugs persist in blood for. The study will specifically look at these three drugs blood levels after taking them for 10 days everyday.

The main objective is to provide information on the potential safety (in terms of preventing virological failure and the development of resistance)of delaying drug doses occasionally by providing information on the decline in drug concentration after dosing has stopped.

Condition Intervention Phase
HIV Infections
Drug: darunavir/ritonavir then atazanavir/ritonavir
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pharmacokinetics of Darunavir/Ritonavir Once Daily and Atazanavir/Ritonavir Once Daily Over 72 Hours Following Drug Intake Cessation

Resource links provided by NLM:

Further study details as provided by St Stephens Aids Trust:

Primary Outcome Measures:
  • Pharmacokinetics [ Time Frame: 30 days (excluding screening and follow-up) ]
    To assess the pharmacokinetics of darunavir/ritonavir once daily and atazanavir/ritonavir once daily over 72 hours following drug intake cessation

Secondary Outcome Measures:
  • Inter-Subject Variability [ Time Frame: 30 days ]
    To assess the inter subject variability in darunavir and atazanavir plasma concentrations over 72 hours following drug intake cessation.

  • Safety and Tolerability [ Time Frame: 30 day (excluding screening and follow up) ]
    To assess the safety and tolerability of darunavir/ritonavir and atazanavir/ritonavir over 10 days of administration

  • Pharmacogenetics [ Time Frame: 30 day (excluding screening and follow up) ]
    To investigate the association between genetic polymorphisms in drug disposition genes and drug exposure

Estimated Enrollment: 25
Study Start Date: April 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everybody
All Subjects will receive the same intervention
Drug: darunavir/ritonavir then atazanavir/ritonavir

Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days

Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days

Other Names:
  • Prezista = TMC114
  • Norvir,
  • Reyataz = BMS-232632

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria within 28 days prior to the baseline visit:

  1. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements
  2. Male or non-pregnant, non-lactating females
  3. Between 18 to 65 years, inclusive
  4. Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive.
  5. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least one month after the study

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.

  1. Any significant acute or chronic medical illness
  2. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
  3. Positive blood screen for hepatitis B surface antigen and/or C antibodies
  4. Positive blood screen for HIV-1 and/or 2 antibodies
  5. Current or recent (within 3 months) gastrointestinal disease
  6. Clinically relevant alcohol or drug use (positive urine drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study
  7. Exposure to any investigational drug or placebo within 3 months of first dose of study drug
  8. Use of any other drugs (unless approved by the Investigator), including over-the-counter medications and herbal preparations, within two weeks prior to first dose of study drug
  9. Females of childbearing potential without the use of effective non-hormonal birth control methods, or not willing to continue practising these birth control methods for at least 30 days after the end of the treatment period

19. Previous allergy to any of the constituents of the pharmaceuticals administered in this trial

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01073761

United Kingdom
St Stephen's Centre
London, United Kingdom, SW10 9TH
Sponsors and Collaborators
St Stephens Aids Trust
Principal Investigator: Marta Boffito, Dr St Stephen's AIDS Trust
  More Information

Responsible Party: Dr Marta Boffito, St Stephen's AIDS Trust Identifier: NCT01073761     History of Changes
Other Study ID Numbers: SSAT 034
Study First Received: February 22, 2010
Last Updated: August 13, 2010

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Atazanavir Sulfate
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on April 21, 2017